Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy

被引:25
作者
Guerrero, MLF [1 ]
Rivas, P [1 ]
Molina, M [1 ]
Garcia, R [1 ]
De Górgolas, M [1 ]
机构
[1] Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Med, Div Infect Dis & Immunol, E-28040 Madrid, Spain
关键词
D O I
10.1086/431487
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Whether asymptomatic human immunodeficiency virus ( HIV) - infected patients can interrupt treatment remains unknown. Methods. We performed a prospective, observational study of 46 patients who started therapy with 1300 CD4(+) cells/ mm(3) and/ or < 70,0000 HIV- 1 RNA copies/ mL. Patients had been receiving highly active antiretroviral therapy ( HAART) for at least 6 months. HAART was discontinued, and plasma HIV- 1 RNA loads and CD4(+) cell counts were determined at 4- month intervals. Results. At the time of HAART discontinuation, the median CD4(+) cell count was 793 cells/ mm(3), and all patients had undetectable viral loads. A rapid decrease of 173 cells/ mm3 in the median CD4+ cell count was observed during the first 4 months after HAART was stopped, followed by a slower decrease of 234 cells/ mm(3) between months 5 and 20. The decrease in the median CD4(+) cell count early after HAART discontinuation was inversely correlated with the increase that occurred during receipt of therapy () and with the count at the time r = 0.653 of HAART discontinuation (). The decrease in the median CD4(+) cell count after the fourth month r = 0.589 without HAART was correlated with the nadir count before HAART initiation () and the increase r = 0.349 during treatment (). The median follow- up duration was 20 months. After 12, 24, and 36 months of r = 0.322 observation, 33 patients ( 71.7%), 22 patients ( 47.8%), and 16 patients ( 34.7%), respectively, remained free of therapy. Adverse clinical events were not seen, and all patients who reinitiated HAART responded rapidly. Conclusion. Selected asymptomatic HIV- infected patients can safely discontinue therapy for prolonged periods of time.
引用
收藏
页码:390 / 394
页数:5
相关论文
共 24 条
[1]   The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy [J].
Anastos, K ;
Barrón, Y ;
Cohen, MH ;
Greenblatt, RM ;
Minkoff, H ;
Levine, A ;
Young, M ;
Gange, SJ .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (04) :256-264
[2]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[3]   Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection [J].
Carcelain, G ;
Tubiana, R ;
Samri, A ;
Calvez, V ;
Delaugerre, C ;
Agut, H ;
Katlama, C ;
Autran, B .
JOURNAL OF VIROLOGY, 2001, 75 (01) :234-241
[4]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[5]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[6]   Antiretroviral therapy for HIV infection in 1996 - Recommendations of an international panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02) :146-154
[7]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[8]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[9]   Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].
Finzi, D ;
Blankson, J ;
Siliciano, JD ;
Margolick, JB ;
Chadwick, K ;
Pierson, T ;
Smith, K ;
Lisziewicz, J ;
Lori, F ;
Flexner, C ;
Quinn, TC ;
Chaisson, RE ;
Rosenberg, E ;
Walker, B ;
Gange, S ;
Gallant, J ;
Siliciano, RF .
NATURE MEDICINE, 1999, 5 (05) :512-517
[10]   Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy [J].
García, F ;
Plana, M ;
Vidal, C ;
Cruceta, A ;
O'Brien, WA ;
Pantaleo, G ;
Pumarola, T ;
Gallart, T ;
Miró, JM ;
Gatell, JM .
AIDS, 1999, 13 (11) :F79-F86